Cinemark Holdings

CNKNYSEUSD

THESIS ALERT

Email me when the CNK thesis changes

Evidence-based analysis, not personalized investment advice. Every alert email carries an unsubscribe link.

Follow on X
$41.32
+$0.14 (+0.34%)Today 1M +13.13%
After hours$41.320.00%

Updated Nov 11, 4:00 PM ET · Regular session · May be delayed

Source valuation snapshot. Not a live recalculation.
Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
Diluted earnings per share from the latest filed annual.
$41.18
Prior regular-session close from the quote source.
$40.73–$41.45
Regular-session low and high so far today.
1.1M
Regular-session shares traded · Nov 11, 4:00 PM ET.
Not yet confirmed
The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
$21.60–$41.67
52-week trading low and high returned by the quote source.

Understand the Business

Why the Stock Moved

Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.

The core investment thesis

Own CNK if Cinemark leverages scale, a geographically diversified circuit (U.S. + Latin America), and premium in-theater amenities to convert box-office and high-margin concessions into outsized cashflow when the film slate and attendance hold, but the stock.

CNK price history

Latest price$41.32Today+$0.14 (+0.34%)
CNK +12.60%S&P 500 -2.42%Since first plotted close
4 hours

Loading recent earnings…

Investment thesis

What must happen next

3 MATERIAL PROPOSITIONS
  • Cinemark's scale and geographic diversification (U.S. + Latin America) keep it an important distribution channel for studios and advertisers, supporting revenue resilience even when individual films underperform.StrengtheningMateriality: High

    Revenue recovered to $3,115,000,000 in FY2025 (near pre-COVID 2019 revenue of $3,283,099,000). If true, revenue will be less volatile and recoveries after weak quarters will be quicker; if false, top-line volatility will rise and pricing power will fall.

    Watch: Major studios shorten or eliminate the exclusive theatrical window and send tentpole releases direct to streaming or day‑and‑date distribution.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Revenue recovered to $3,115,000,000 in FY2025 (near pre-COVID 2019 revenue of $3,283,099,000).

    Open source ↗
  • Because most facility leases and many costs are fixed at the theater level, stable attendance and improved per-guest pricing/concession mix should produce outsized operating income and cash flow (operating leverage) as incremental box-office is largely incremental profit after variable film.HoldingMateriality: High

    2019 operating income of $338,387,000 demonstrates the business can generate substantial operating profit at scale. If true, modest revenue growth or return-to-normal attendance will expand operating income and free cash flow, enabling dividends and de‑leveraging; if false, fixed costs and inflation will compress margins and cash generation.

    Watch: Sustained weak content slate or underperforming tentpoles that reduce attendance (lowering revenue without proportionate cost decline).

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    2019 operating income of $338,387,000 demonstrates the business can generate substantial operating profit at scale.

    Open source ↗
  • Cinemark's Latin American circuit offers growth optionality that can outpace U.S. markets if local box office expands with population/retail growth and Hollywood tentpoles continue to resonate regionally.HoldingMateriality: Medium

    Filings: Latin America circuit operated 193 theaters and 1,396 screens across 13 countries and preliminary Latin American industry box office was ~ $1.2 billion for 2025. If true, international revenue growth will supplement U.S. performance and reduce reliance on a single market; if false, macro, currency or political shocks will amplify downside to consolidated revenue.

    Watch: Currency devaluations, repatriation limits or sudden political instability in key Latin American markets that reduce attendance and profitability.

    Supporting sources

    Source notes are factual paraphrases; read the original disclosures below.

    Filings: Latin America circuit operated 193 theaters and 1,396 screens across 13 countries and preliminary Latin American industry box office.

    Open source ↗
Full investment case & evidence

Loading the original research archive…

Original research

Cinemark's scale and geographic diversification (U.S. + Latin America) keep it an important distribution channel for studios and advertisers, supporting revenue resilience even when individual films underperform. If true, revenue will be less volatile and recoveries after weak quarters will be quicker; if false, top-line volatility will rise and pricing power will fall.

Because most facility leases and many costs are fixed at the theater level, stable attendance and improved per-guest pricing/concession mix should produce outsized operating income and cash flow (operating leverage) as incremental box-office is largely incremental profit after variable film. If true, modest revenue growth or return-to-normal attendance will expand operating income and free cash flow, enabling dividends and de‑leveraging; if false, fixed costs and inflation will compress margins and cash generation.

Cinemark's Latin American circuit offers growth optionality that can outpace U.S. markets if local box office expands with population/retail growth and Hollywood tentpoles continue to resonate regionally. If true, international revenue growth will supplement U.S. performance and reduce reliance on a single market; if false, macro, currency or political shocks will amplify downside to consolidated revenue.

All standing thesis claims
Original report summary

Cinemark leverages scale, a geographically diversified circuit (U.S. + Latin America), and premium in-theater amenities to convert box-office and high-margin concessions into outsized cashflow when the film slate and attendance hold, but the stock.

Evidence assessed Nov 12, 2026. Expand each conclusion for its evidence and what would change it. Thesis evidence—not a buy or sell recommendation.

Bull case and bear case

Bull case and bear case for Cinemark Holdings

Where the evidence on Cinemark Holdings stands: Holding on the latest evidence (Nov 12, 2026). Of its 3 thesis points, 1 strengthening and 2 holding.

Bull case: what the evidence supports

  • Cinemark's scale and geographic diversification (U.S. + Latin America) keep it an important distribution channel for studios and advertisers, supporting revenue resilience even when individual films underperform.

    sec.gov ↗

  • Because most facility leases and many costs are fixed at the theater level, stable attendance and improved per-guest pricing/concession mix should produce outsized operating income and cash flow (operating leverage) as incremental box-office is largely incremental profit after variable film.

    sec.gov ↗

  • Cinemark's Latin American circuit offers growth optionality that can outpace U.S. markets if local box office expands with population/retail growth and Hollywood tentpoles continue to resonate regionally.

    sec.gov ↗

Bear case: what would count against it

  • Major studios shorten or eliminate the exclusive theatrical window and send tentpole releases direct to streaming or day‑and‑date distribution.

    sec.gov ↗

  • Sustained weak content slate or underperforming tentpoles that reduce attendance (lowering revenue without proportionate cost decline).

    sec.gov ↗

  • Currency devaluations, repatriation limits or sudden political instability in key Latin American markets that reduce attendance and profitability.

    sec.gov ↗

Thesis-Break Engine

Thesis-break watch · Cinemark Holdings

Loading the break-condition record for Cinemark Holdings.

How the Thesis-Break Engine works →Historical outcomes are measured against the market after past breaks of the same kind, across all companies. Not a prediction.

MARKET + FINANCIAL SNAPSHOT

The numbers behind the thesis

Sourced from filings and market data

What Changed

  1. Mixed
    Reported results of operations (earnings release).

    Cinemark Holdings filed an SEC 8-K on 2026-11-03: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

  2. Mixed
    Director or principal officer change.

    Cinemark Holdings filed an SEC 8-K on 2026-08-12: Director or principal officer change. It is a dated development that tests the current thesis.

  3. Mixed
    Reported results of operations (earnings release).

    Cinemark Holdings filed an SEC 8-K on 2026-07-30: Reported results of operations (earnings release). It is a dated development that tests the current thesis.

Risks / falsifiers

What could break the thesis

  • Major studios shorten or eliminate the exclusive theatrical window and send tentpole releases direct to streaming or day‑and‑date distribution.
  • Sustained weak content slate or underperforming tentpoles that reduce attendance (lowering revenue without proportionate cost decline).
  • Currency devaluations, repatriation limits or sudden political instability in key Latin American markets that reduce attendance and profitability.

CNK news

Loading headlines…

Financial statements

CNK income statement

Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

CNK: quick answers

Have members of Congress traded CNK?
8 trades in CNK have been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed CNK trade
Which well-known investors own CNK?
1 of the 37 well-known funds tracked here reported CNK shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios

CNK in well-known investors’ portfolios

1 of 37 funds reported CNK shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.

FundOf its portfolioValueChangeQuarter
Ray DalioBridgewater Associates0.00%$515KNewQ2 2026

Every fund’s portfolio

ScoutJUST THIS STORY

LET’S MAKE THIS USEFUL · 1 OF 5

How would you like me to explain this?

Tell me what you want from this read. Start with a quick note, then adjust the details. Your other stories stay as they are.

We’ll remember your view of this story. The published article stays unchanged.

THIS STORY’S READING VIEWStandard · The whole picture

Clear explanations with context. Both sides of the evidence.